CCAGW Urges West Virginia Legislators to Oppose Senate Bill 325 | Council For Citizens Against Government Waste

CCAGW Urges West Virginia Legislators to Oppose Senate Bill 325

Letters to Officials

Senate Health and Human Resources Committee
Room 451-M, Building 1, State Capitol Complex
1900 Kanawha Blvd. E
Charleston, West Virginia, 25305

Dear Senator,

The Senate Health and Human Resources Committee will have a hearing on SB325, which will make changes to the federal 340B program.  On behalf of the 7,722 members and supporters of the Council for Citizens Against Government Waste (CCAGW) in West Virginia, I urge you to oppose this bill.  Congress created the 340B program in 1992 to fix a problem it created only two years earlier when it implemented government set price controls, or rebates, in the Medicaid drug benefit program.  As a condition to participating in Medicaid, pharmaceutical companies must partake in the 340B program by giving discounts between 20-50 percent to certain federally funded facilities and disproportionate share hospitals that receive government subsidies to treat large numbers of Medicaid patients.  But the statute does not define “patient” or require covered entities to pass on drug savings to patients.

A January 2018 House Energy and Commerce Committee report on 340B identified insufficient oversight, unreliable data, and inadequate reporting requirements.  The program’s failures were the result of several factors, including the lack of clear statutory intent and definition of an eligible patient, as well as lax requirements to report savings and how that money is used.  A November 2021 Xcenda study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” provides further evidence of how the 340B safety-net program is being exploited by failing to help low income and vulnerable individuals get access to low-cost prescription drugs.  Instead, it is boosting hospitals’ coffers and their contract pharmacies’ profits that are largely located in areas that do not serve low-income people.  The healthcare data analytics firm IQVIA released an annual study, “The 340B Drug Discount Program Exceeds $100B in 2022,” found ongoing misuse of the funds by hospitals and contract pharmacies, and that patients are still not getting their benefits.

A September 24, 2022,  New York Times article about Richmond Community Hospital in Virginia, owned by Bon Secours, found that instead of reinvesting profits from 340B drug sales into its facilities and improve patient care,  the money was being used instead to invest in facilities in the city’s wealthier neighborhoods.  Dr. Lucas English, who worked in the hospital’s emergency department until 2018, said, “Bon Secours was basically laundering money through this poor hospital to its wealthy outposts … It was all about profits.”  Dr. Peter B. Bach, who has written about the increased number of clinics opened in wealthier areas using 340B profits, said the hospitals are “nakedly capitalizing on programs that are intended to help poor people.”  Additionally, language in SB325 related to manufacturers’ obligations under the program is premature as this case and other hospitals across the country are still under federal investigation.

I urge you to contact your congressional delegation and ask them to reform the program, which would include providing a clear definition of a patient.  CCAGW’s preference is the patient is indigent, not eligible for Medicaid, and does not have insurance.  Again, I ask that you vote against SB325.

Tom Schatz
President, CCAGW




Letter Type: 
Organization Letters

Sign Up For Email Updates

Optional Member Code